by David Cassak
Nearly a decade ago, medical device giant Medtronic Inc. shook up itself and the device industry with a series...
A decade ago, Medtronic shook up itself and the device industry with a series of large deals over a short period of time. In the process, the company tranformed itself from a leader in cardiac rhythm management into the industry's largest, most diversified device company. More recently, the company has been quieter, focusing on smaller deals, both acquisitions and minority investments. In But in this interview, Medtronic's head of Corporate Development, Bob White, says that Medtronic is ready to deal again and talks about the kinds of companies it's interested in.
by David Cassak
Nearly a decade ago, medical device giant Medtronic Inc. shook up itself and the device industry with a series...
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.
Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.